Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > BUSINESS
BUSINESS
- MSD Paid 19.4 Billion Yen to Healthcare Professionals in 2013
September 25, 2014
- Gilead Sciences Submits NDA for Ledipasvir/Sofosbuvir Combination for Genotype 1 Chronic Hepatitis C
September 25, 2014
- AnGes MG to Start Collategene Administration in PIII Study in US as Early as October
September 25, 2014
- Ibandronate Oral Agent to Be Filed for Japan Approval in 2015: Chugai, Taisho
September 24, 2014
- Meiji Seika Pharma Seeks New Indication for Laserphyrin
September 24, 2014
- Mediceo Sets to Increase Qualified Reps to 2,000, Enter Contract PMS Biz within 3 Years
September 22, 2014
- Bristol-Myers Submits NDA for Malignant Melanoma Drug Ipilimumab
September 22, 2014
- Additional Indication Approved for MTPC’s Telavic
September 22, 2014
- RaQualia Wins Use-Patent Allowance for EP4 Antagonist in US
September 22, 2014
- Bayer’s Japan Open Innovation Center Now Up and Running
September 22, 2014
- Sadao Furuichi to Double as Heads of Kracie Pharma, Kracie Pharmaceutical
September 22, 2014
- Huya Bioscience International Opens Tokyo Office
September 19, 2014
- MTPC Generic Arm Seeks to Quickly Broaden Product Lineup, New Alliance a Possibility: Pres.
September 18, 2014
- Takeda to Reshuffle Global Structure in April
September 18, 2014
- Toray Partners with German Firm on Sales of Hemoperfusion Device in Europe
September 18, 2014
- Allergan, Shionogi Tie Up for Sales of Eyelash Hypotrichosis Agent
September 18, 2014
- Bayer Paid 10.1 Billion Yen to Healthcare Professionals in 2013
September 18, 2014
- Bristol-Myers’ 2013 Payments to Health Professionals Total 4.9 Billion Yen
September 18, 2014
- Eisai Inks Two Joint Research Deals for Novel Antimalarial Agents
September 18, 2014
- Kaketsuken Wins Grants for Dengue Vaccine Program from GHIT Fund
September 18, 2014
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…